Stanley G Rockson1, Wen Tian2, Xinguo Jiang2, Tatiana Kuznetsova3, Francois Haddad1, Jamie Zampell4, Babak Mehrara4, Joshua P Sampson1, Leslie Roche1, Jinah Kim5, Mark R Nicolls2. 1. Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 2. Department of Medicine, VA Palo Alto Health Care System/Stanford University, Palo Alto, California, USA. 3. Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium. 4. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA. 5. Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Abstract
BACKGROUND: Lymphedema is a common condition affecting millions around the world that still lacks approved medical therapy. Because ketoprofen, an NSAID, has been therapeutic in experimental lymphedema, we evaluated its efficacy in humans. METHODS: We first performed an exploratory open-label trial. Patients with either primary or secondary lymphedema received ketoprofen 75 mg by mouth 3 times daily for 4 months. Subjects were evaluated for changes in histopathology, with skin thickness, limb volume, and tissue bioimpedance changes serving as secondary endpoints. Based on our encouraging findings, we next conducted a placebo-controlled trial, with the primary outcome defined as a change in skin thickness, as measured by skin calipers. Secondary endpoints for this second study included histopathology, limb volume, bioimpedance, and systemic inflammatory mediators. RESULTS: We enrolled 21 lymphedema patients in the open-label trial, from November 2010 to July 2011. Histopathology and skin thickness were significantly improved at 4 months compared with baseline. In the follow-up, double-blind, placebo-controlled trial, we enrolled 34 patients from August 2011 to October 2015, with 16 ketoprofen recipients and 18 placebo-treated subjects. No serious adverse events occurred. The ketoprofen recipients demonstrated reduced skin thickness, as well as improved composite measures of histopathology and decreased plasma granulocyte CSF (G-CSF) expression. CONCLUSION: These 2 exploratory studies together support the utility of targeted antiinflammatory therapy with ketoprofen in patients with lymphedema. Our results highlight the promise of such approaches to help restore a failing lymphatic circulation. TRIAL REGISTRATION: ClinicalTrials.gov NCT02257970.
RCT Entities:
BACKGROUND:Lymphedema is a common condition affecting millions around the world that still lacks approved medical therapy. Because ketoprofen, an NSAID, has been therapeutic in experimental lymphedema, we evaluated its efficacy in humans. METHODS: We first performed an exploratory open-label trial. Patients with either primary or secondary lymphedema received ketoprofen 75 mg by mouth 3 times daily for 4 months. Subjects were evaluated for changes in histopathology, with skin thickness, limb volume, and tissue bioimpedance changes serving as secondary endpoints. Based on our encouraging findings, we next conducted a placebo-controlled trial, with the primary outcome defined as a change in skin thickness, as measured by skin calipers. Secondary endpoints for this second study included histopathology, limb volume, bioimpedance, and systemic inflammatory mediators. RESULTS: We enrolled 21 lymphedemapatients in the open-label trial, from November 2010 to July 2011. Histopathology and skin thickness were significantly improved at 4 months compared with baseline. In the follow-up, double-blind, placebo-controlled trial, we enrolled 34 patients from August 2011 to October 2015, with 16 ketoprofen recipients and 18 placebo-treated subjects. No serious adverse events occurred. The ketoprofen recipients demonstrated reduced skin thickness, as well as improved composite measures of histopathology and decreased plasma granulocyte CSF (G-CSF) expression. CONCLUSION: These 2 exploratory studies together support the utility of targeted antiinflammatory therapy with ketoprofen in patients with lymphedema. Our results highlight the promise of such approaches to help restore a failing lymphatic circulation. TRIAL REGISTRATION: ClinicalTrials.gov NCT02257970.
Authors: Janice N Cormier; Robert L Askew; Kristi S Mungovan; Yan Xing; Merrick I Ross; Jane M Armer Journal: Cancer Date: 2010-11-15 Impact factor: 6.860
Authors: Peter Baluk; Ram P Naikawadi; Shineui Kim; Felipe Rodriguez; Dongwon Choi; Young-Kwon Hong; Paul J Wolters; Donald M McDonald Journal: Am J Pathol Date: 2020-10-08 Impact factor: 4.307
Authors: Bailey H Duhon; Thien T Phan; Shannon L Taylor; Rachelle L Crescenzi; Joseph M Rutkowski Journal: Int J Mol Sci Date: 2022-06-14 Impact factor: 6.208
Authors: Xinguo Jiang; Wen Tian; Eric J Granucci; Allen B Tu; Dongeon Kim; Petra Dahms; Shravani Pasupneti; Gongyong Peng; Yesl Kim; Amber H Lim; F Hernan Espinoza; Matthew Cribb; J Brandon Dixon; Stanley G Rockson; Gregg L Semenza; Mark R Nicolls Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808
Authors: Matthew T Cribb; Lauren F Sestito; Stanley G Rockson; Mark R Nicolls; Susan N Thomas; J Brandon Dixon Journal: Int J Mol Sci Date: 2021-04-24 Impact factor: 6.208
Authors: Jie Deng; Mary S Dietrich; Kenneth J Niermann; Robert J Sinard; Anthony J Cmelak; Sheila H Ridner; Jill Gilbert; Barbara A Murphy Journal: Int J Radiat Oncol Biol Phys Date: 2020-10-14 Impact factor: 8.013
Authors: Wen Tian; Xinguo Jiang; Dongeon Kim; Torrey Guan; Mark R Nicolls; Stanley G Rockson Journal: Front Pharmacol Date: 2020-08-19 Impact factor: 5.810